Genoskin raises $8.7M series A

We are excited to announce that Genoskin, a leader in developing ex vivo human skin platforms for testing drugs and medical devices, has raised $8.7 million (€8M) in Series A funding. The investment will fuel the company’s global expansion, enhance its service offerings, and further its mission to provide ethical, human-relevant alternatives to animal testing.

Led by OCCTE (FPCI Occidev Impacts), Captech Santé, GSO Innovation, and CA Toulouse 31 Initiatives (CAT31i), the round includes $5.4 million (€5M) in equity investment and $3.3 million (€3M) in non-dilutive financing in structured bank debt, provided by Bpifrance and local banking partners: BNP Paribas, Caisse d’Epargne, and Crédit Agricole. Genoskin plans to double its workforce and expand its commercial presence in key global markets, with new facilities planned in Salem, MA, US and Toulouse, France.

Genoskin’s innovative human skin models provide more predictive insights into the toxicity and efficacy of drugs and medical devices than traditional animal models. The company’s ex vivo platforms use ethically sourced human skin, which remains viable for up to seven days, offering a sustainable, human-relevant alternative for biotech, pharma, and cosmetics companies.

“This funding gives Genoskin the resources to scale globally, strengthen our presence in key markets and accelerate the development of our innovative platforms. As a company built on ethical innovation, we are proud to offer sustainable, human-relevant alternatives to animal testing. This investment validates our strategy and reinforces our position as a leader in predictive immunotoxicology using live human skin models. With the support of our investors, Genoskin is well-positioned to drive meaningful change in how biotherapies are developed, ultimately bringing safer treatments to patients worldwide.”
– Pascal Descargues, Ph.D., Founder and CEO of Genoskin.

To meet the rising international demand for its services, Genoskin is expanding its operations with new production sites in both France and the US. In 2026, the company will open a 7,500 ft² (700 m²) facility in Salem, MA, followed by a 10,700 ft² (1,000 m²) site in Toulouse, France, in 2027. These expansions will enable Genoskin to double its production capacity, particularly for its human skin models, and introduce the production of fresh human primary mast cells for next-day delivery in the US.
This expansion will be complemented by increased automation in industrial production, supporting Genoskin’s growth while maintaining the highest standards of quality control. The company’s scale-up plans are designed to deliver efficient, reliable services to customers around the world, helping them develop safer, more effective therapies.

In addition to expanding its infrastructure, Genoskin will continue to enhance its scientific leadership by developing new biosimulation platforms and human immune models that focus on reducing reliance on animal testing. These platforms are expected to support new immune-centric service offerings by 2027, strengthening the company’s role as a leader in immunotoxicology and providing vital insights into the safety and efficacy of drug candidates.

“Captech Santé is pleased to contribute to the financing of Genoskin, a company capable of setting new global standards in the development of injectable drugs and that already counts most major global pharmaceutical companies among its clients,”
– Alexandre Demailly, Investor at Captech Santé

Genoskin’s innovative approach is at the forefront of a revolution in drug development. By offering scalable, ethical, and human-relevant alternatives to traditional animal models, the company is shaping the future of preclinical testing. As regulatory bodies continue to push for more humane and effective testing methods, Genoskin is well-positioned to lead the charge in delivering safer, more predictive drug development insights for the benefit of patients worldwide.